Event context and recent price performance

MiniMed Group (MMED) stock has been moving without a clear single news catalyst, with a 1-day gain of 1.3% and a 7-day gain of 9.1%, while trading down 10.1% over the past month.

At the current share price of $11.87, MiniMed Group’s short term momentum has been positive, with a 7 day share price return of 9.1%. However, this follows a share price decline of 10.1% over the past month and 35.8% year to date, which suggests that recent gains are still occurring within a weaker longer term trend in how the market is weighing its growth prospects and risks.

If you are weighing MiniMed Group’s recent swings and want a broader set of ideas in healthcare technology, it can be useful to scan 34 healthcare AI stocks.

With MiniMed Group trading at $11.87, carrying a reported loss and sitting at a steep discount to analyst targets and intrinsic value estimates, is this a potential entry point or is the market already pricing in future growth?

Preferred Price-to-Sales of 1.1x: Is it justified?

On a P/S of 1.1x at a share price of $11.87, MiniMed Group trades at a clear discount to both its US Medical Equipment industry peers on 2.8x and a selected peer group on 3.9x. That signals the market is assigning a lower value to each dollar of MiniMed Group’s $2,989 revenue than to comparable companies.

The P/S multiple focuses on how much investors are paying for each dollar of revenue, which is particularly useful for a company that is currently loss making. For MiniMed Group, this lens matters because revenue is present but net income is a loss of $320, and revenue is forecast to grow by 8.9% per year while earnings are forecast to grow strongly from a low base.

The combination of revenue growth forecasts, expectations that the company becomes profitable within three years, and a P/S of 1.1x suggests the market is cautious about execution, balance sheet strength and the new leadership team, despite analysts being in solid agreement on future earnings growth. Compared with both the industry average of 2.8x and the peer average of 3.9x, the current P/S stands out as materially lower. This frames MiniMed Group as valued more conservatively than many medical equipment stocks with similar revenue profiles.

Result: Price-to-Sales of 1.1x (UNDERVALUED)

However, the company is still loss making and depends heavily on diabetes device adoption, so any product setbacks or slower uptake could challenge today’s cautious pricing.

Another view using our DCF model

While the P/S of 1.1x points to a conservative price tag, our DCF model presents a different view of potential value. MiniMed Group is trading at $11.87 compared with an estimated future cash flow value of $81.60, which suggests it screens as heavily undervalued. The question is whether you place more weight on the cash flow assumptions or on the market’s caution.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out MiniMed Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of caution and optimism in the numbers, it makes sense to review the full picture now and decide where you stand using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If MiniMed Group has caught your attention, do not stop here. A broader watchlist can help you spot opportunities that fit your style before the crowd.

• Target income-focused opportunities by scanning established companies offering strong payouts and reliable track records through the 10 dividend fortresses.
• Zero in on quality companies that may be trading at conservative prices by checking the 48 high quality undervalued stocks.
• Aim for resilience first by focusing on companies with stronger finances using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.